U.S. markets closed
  • S&P Futures

    3,933.25
    -3.50 (-0.09%)
     
  • Dow Futures

    33,617.00
    -8.00 (-0.02%)
     
  • Nasdaq Futures

    11,491.75
    -17.75 (-0.15%)
     
  • Russell 2000 Futures

    1,806.20
    -1.80 (-0.10%)
     
  • Crude Oil

    72.77
    +0.76 (+1.06%)
     
  • Gold

    1,795.20
    -2.80 (-0.16%)
     
  • Silver

    22.80
    -0.12 (-0.53%)
     
  • EUR/USD

    1.0501
    -0.0013 (-0.13%)
     
  • 10-Yr Bond

    3.4080
    -0.1050 (-2.99%)
     
  • Vix

    22.68
    +0.51 (+2.30%)
     
  • GBP/USD

    1.2190
    -0.0015 (-0.12%)
     
  • USD/JPY

    137.0170
    +0.4930 (+0.36%)
     
  • BTC-USD

    16,845.42
    -186.12 (-1.09%)
     
  • CMC Crypto 200

    395.51
    -6.52 (-1.62%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • Nikkei 225

    27,534.45
    -151.95 (-0.55%)
     

BIOLASE EXPANDS INTELLECTUAL PROPERTY PORTFOLIO WITH NEW UNITED STATES AND FOREIGN PATENTS

Company continues to lead the dental laser industry with 302 issued and 31 pending patents

LAKE FOREST, Calif., July 25, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that the company has received five new United States patents and seven new foreign patents in the last 12 months.

BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)
BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

In June, the company received notice from the Korean Intellectual Property Office of the Decision to Grant, "KR #2412063 titled Pre-Initiated Optical Fibers for Medical Applications," an important addition to BIOLASE's Korean IP portfolio. Also, the Canadian Intellectual Property Office (CIPO) granted, #2,935,691 titled Dual Wavelength Laser Treatment Device.

Two additional recent patents are US #11,250,941 titled Dental Laser Interface System and Method issued on Feb. 15, 2022, issued in the U.S. and BR112015008998-4, Handpiece Assembly for Laser Treatment Device issued in Brazil on Feb. 8, 2022.

BIOLASE maintains an industry-leading portfolio of intellectual property ("IP") with 302 issued and 31 pending applications.

"BIOLASE's proprietary laser products represent decades of innovative research and incorporate many patented and patent-pending technologies specifically designed and tested to provide biologically and clinically superior performance with a more comfortable patient experience and faster recovery times," commented BIOLASE Vice President of Innovation and Business Development, William Brown, Jr.

"The new patents are all related to the flagship Waterlase laser systems and market-leading Epic diode technologies, and expand the protection of BIOLASE's key IP well into the future," said John Beaver, President and Chief Executive Officer of BIOLASE.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-expands-intellectual-property-portfolio-with-new-united-states-and-foreign-patents-301592167.html

SOURCE BIOLASE, Inc.